KPKanila Perera

Kanila Perera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kanila Perera has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Foreign body-type giant cell reaction post intracranial endovascular clot retrieval: a postmortem case

    by Kanila Perera, Nadya Lazareva, Catriona McLean, Geoffrey Cloud

    Background and aims: Endovascular clot retrieval (ECR) has revolutionised acute ischaemic stroke management. While procedural safety is well established, little attention has been paid to vascular responses to hydrophilic polymer coatings used on retrieval devices. This report presents postmortem histopathological findings implicating a foreign body giant cell reaction secondary to hydrophilic polymer exposure as a cause of recurrent stroke following ECR. Methods: A detailed clinical and neuropathological review was conducted on a 72-year-old patient who experienced three sequential ischaemic strokes within 4 months following ECR and angioplasty of a right middle cerebral artery (M2) occlusion. Limited postmortem examination of the heart and brain was undertaken with histopathological and immunoperoxidase staining to assess potential vascular inflammatory mechanisms. Results: Postmortem examination demonstrated multiple infarcts of differing ages, diffuse atherosclerotic change and a florid multinucleated giant cell reaction containing non-polarisable basophilic material along the luminal surface of the right M2 segment and adjacent vessels. The internal elastic lamina remained intact, with only focal fibrinoid necrosis and sparse medial inflammation. No amyloid angiopathy, vasculitis or cardiac embolic source was identified. The morphological features were consistent with a chronic inflammatory response to embolised hydrophilic polymer coating material from prior endovascular instrumentation. Conclusions: This case highlights an under-recognised mechanism of post-ECR recurrent stroke linked to hydrophilic polymer-induced vascular inflammation. If recognised antemortem, immunosuppression may be more effective than usual secondary stroke prevention treatments.

  • Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis

    by Ning Kam, Kanila Perera, Ella Zomer, Danny Liew, Zanfina Ademi

    Background Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin-kexin type 9 (PCSK9). The comparison of inclisiran with statin versus statin alone in the ORION-10 trial demonstrated significant reductions in low-density lipoprotein cholesterol (LDL-C). Our study explored whether the use of inclisiran with statin versus statin alone for secondary prevention of cardiovascular events is cost effective from the Australian healthcare perspective, based on the price of currently available PCSK9 inhibitors. Methods A Markov model was developed based on the ORION-10 trial to model outcomes and costs incurred by patients over a lifetime analysis. The three health states were ‘alive with cardiovascular disease (CVD)’, ‘alive with recurrent CVD’, and ‘dead’. Cost and utilities were estimated from published sources. The cost of inclisiran was estimated from the annual cost of evolocumab, a PCSK9 inhibitor currently available in Australia (AU$6334, based on 2020 data). Outcomes of interest were incremental cost-effectiveness ratios (ICERs) in terms of cost per quality-adjusted life-year (QALY) and cost per year of life saved (YoLS). All costs, QALYs and YoLS were discounted at 5% per annum in line with Australian standards. Results Among 1000 subjects followed-up over a lifetime analysis, inclisiran with statin compared with statin alone prevented 235 non-fatal myocardial infarctions (NFMIs; 151 NFMI and 84 repeat NFMI cases) and 114 coronary revascularisation cases, and increased years of life by 0.549 (discounted) and QALYs by 0.468 (discounted). At an annual price of AU$6334, the net marginal cost was AU$58,965 per person. The above values equated to ICERs of AU$107,402 per YoLS and AU$125,732 per QALY gained. Assuming a willingness-to-pay threshold of AU$50,000, inclisiran would have to be priced 60% lower than other available PCSK9 inhibitors to be considered cost effective. Conclusions As an adjunct therapy to statin treatment in those who have persistently elevated LDL-C despite optimal statin therapy, inclisiran is effective in reducing cardiovascular events in patients with atherosclerotic CVD. Inclisiran is not cost effective from the Australian healthcare perspective, assuming acquisition costs of current PCSK9 inhibitors. The cost of inclisiran would have to be 60% lower than that of evolocumab.


  • Sacubitril-valsartan versus enalapril for acute decompensated heart failure: a cost-effectiveness analysis

    by Kanila Perera, Zanfina Ademi, Danny Liew, Ella Zomer

    The Comparison of Sacubitril–Valsartan versus Enalapril on Effect on NT-proBNP in Patients Stabilised from an Acute Heart Failure Episode (PIONEER-HF) trial demonstrated significant reductions in N-terminal pro-B-type natriuretic peptide. Our study explored the cost-effectiveness of the use of sacubitril-valsartan versus enalapril in acute decompensated heart failure from the Australian healthcare perspective. A Markov model was designed using data from the PIONEER-HF trial to model the clinical progress and costs of patients over a lifetime time horizon. The model consisted of three health states: ‘alive and event-free’, ‘alive after non-fatal hospitalisation for acute decompensated heart failure’ or ‘dead’. Costs and utilities were estimated from published sources. The cost of sacubitril-valsartan (per the Australian pharmaceutical benefits schedule) was AU$7.08/day. Outcomes of interest were the incremental cost-effectiveness ratios in terms of cost per quality-adjusted life year gained and cost per year of life saved. Cost and benefits were discounted at 5.0% per annum. Compared to enalapril, sacubitril-valsartan was estimated to cost an additional AU$7464 (discounted) per person, but lead to 0.127 years of life saved (discounted) and 0.096 quality-adjusted life years gained (discounted) over a lifetime analysis. These equated to incremental cost-effectiveness ratios of AU$58,629/year of life saved (US$41,795, EU€58,629, GBP£32,001) and AU$77,889/quality-adjusted life year gained (US$55,526, EU€49,202, GBP£42,504). We have assumed a threshold of AU$50,000/quality-adjusted life year gained to suggest cost-effectiveness. At its current acquisition price, sacubitril-valsartan in comparison to enalapril is not likely to be cost-effective in the management of acute decompensated heart failure in Australia. A price reduction of more than 25% would confer cost-effectiveness.